Accessibility Menu
Ainos logo

Ainos(NASDAQ) AIMD

Current Price$1.48
Market Cap$11.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-100%
1 Year-46%
1 Month-22%
Ainos last closing stock price
MetricPriceDate
Last closeUSD 1.402026-07-24
Ainos stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.15%USD 1.652026-07-17
1 month-22.22%USD 1.802026-06-24
3 month-20.9%USD 1.772026-04-24
Year to date-14.63%USD 1.642025-12-31
1 year-46.15%USD 2.602025-07-24
3 year-94.33%USD 24.702023-07-25
5 year-99.61%USD 356.252021-07-23
Since inception-100%USD 35,625.041996-08-08

Ainos Financials at a Glance

Market Cap

$11.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.11K

Net Income (TTM)

-$13.94M

EPS (TTM)

-$2.90

P/E Ratio

-0.48

Dividend

$0.00

Beta (Volatility)

0.35 (Low)

Price

$1.48

Volume

766

Open

$1.50

Previous Close

$1.48

Daily Range

$1.42 - $1.50

52-Week Range

$1.26 - $4.50

Estimated Earnings Date

May 11, 2026

AIMD News

Foolcom-Featured.png

Ainos Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ainos

Ainos develops medical tests and digital scent technology for healthcare and industry. Its products help detect diseases and monitor health in real time. The company’s tools support both patients and businesses with practical, easy-to-use solutions.

Sniffing Out Solutions: Products and Services

  • AI Nose Platform: Digital scent detection system for healthcare, robotics, and manufacturing (revenue share not disclosed).
  • Point-of-Care Testing: Devices for rapid disease detection, including breath and vaginal health tests (revenue share not disclosed).
  • VELDONA Platform: Low-dose oral interferon treatments for rare and infectious diseases in humans and animals (revenue share not disclosed).
  • Pet Health Supplements: VELDONA Pet products for canine and feline wellness, sold in Taiwan.
  • Cloud-Based Test Management: App for managing test results and data, used by individuals and businesses.

Growth and Expansion: The Scent Trail

  • Launched AI Nose platform through partnerships with ASE Technology Holding and others in 2025.
  • Introduced "SmellTech-as-a-Service" subscription model in 2025 for recurring revenue.
  • Discontinued COVID-19 antigen test kit in Q1 2024, shifting focus to new products.
  • Raised capital via At The Market (ATM) offering in 2024 and 2025.

What Makes Ainos Stand Out

Ainos combines digital scent technology with artificial intelligence for new health and industrial uses. Its subscription model creates recurring revenue and supports capital efficiency. The company leverages partnerships to expand reach and reduce development costs.

Five Things You Need to Know

  • Q2 2025 revenue was $4,663, down 83.7% from Q2 2023.
  • H1 2025 revenue was $110,870, up 435% from H1 2024.
  • Q2 2025 net loss was approximately $4.1 million, 28% higher than Q2 2024.
  • Cash and cash equivalents were approximately $1.2 million as of June 30, 2025.
  • Company raised $1.8 million through equity offerings in 2025.

Bottom Line

Ainos has shifted from COVID-19 tests to digital scent and health products. The company relies on innovation and partnerships but faces ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Technology Hardware, Storage and Peripherals

Sector

Information Technology

Employees

41

CEO

Chun Hsien Tsai

Website

www.ainos.com

Headquarters

Houston, TX 92108, US

AIMD Financials

Key Financial Metrics (TTM)

Gross Margin

-26296.83%

Operating Margin

-72393.48%

Net Income Margin

-76996.25%

Return on Equity

-160.55%

Return on Capital

-75.37%

Return on Assets

-63.15%

Earnings Yield

-2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.52M

Volume

766

Avg. Volume

365.10K

Financials (TTM)

Gross Profit

-$4.76M

Operating Income

-$13.11M

EBITDA

-$8.46M

Operating Cash Flow

-$4.37M

Capital Expenditure

-$9.46K

Free Cash Flow

-$4.38M

Cash & ST Invst.

$2.84M

Total Debt

$13.81M

Ainos Performance Analysis

Ainos annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,519,627492.0%
20232023-12-31USD 122,112-96.5%
20242024-12-31USD 20,729-83.0%
20252025-12-31USD 124,157499.0%
Ainos sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-95.6%
Q32025-09-30-53.5%
Q42025-12-31413.2%
Q12026-03-31-98.6%
Ainos annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -25.6899.5%
20232023-12-31USD -16.80-34.6%
20242024-12-31USD -7.82-53.5%
20252025-12-31USD -3.46-55.8%
Ainos sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3099.5%
Q32025-09-3035.4%
Q42025-12-31-32.8%
Q12026-03-3151.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$161.00

-99.8%

Gross Profit

-$1.17M

-7.8%

Gross Margin

-7296.12%

N/A

Market Cap

$11.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$291.08K

N/A

Employees

41

N/A

Net Income

-$2.46M

+25.1%

EBITDA

-$1.11M

+42.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.84M

+8.1%

Total Debt

$13.81M

+15.1%

Accounts Receivable

$23.00

-74.7%

Inventory

$315.64K

+122.5%

Long Term Debt

$9.00M

-18.2%

Short Term Debt

$4.81M

+381.3%

Return on Assets

-63.15%

N/A

Return on Invested Capital

-83.32%

N/A

Free Cash Flow

-$991.96K

+21.2%

Operating Cash Flow

-$983.42K

+19.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DAREDare Bioscience, Inc.
$1.28+1.59%
BLRXBioLineRx Ltd.
$2.82-1.40%
MBRXMoleculin Biotech, Inc.
$2.12+1.92%
ICUSeaStar Medical Holding Corporation
$3.75+0.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About AIMD

What is the current price of Ainos?

Ainos is trading at $1.48 per share.

What is the 52-week range for Ainos?

Over the past 52 weeks, Ainos has traded between $1.26 and $4.50.

How much debt does Ainos have?

As of the most recent reporting period, Ainos reported total debt of $13.81M.

How much cash does Ainos have on hand?

Ainos reported $2.84M in cash and cash equivalents in its most recent financial results.

What is Ainos’s dividend yield?

Ainos does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services